Birmingham, AL, United States of America

George M Shaw

This inventor holds 20 USPTO granted patents and 6 published patent applications, plus 3 CIPO patents and 2 EPO patents, primarily in HIV Vaccine Development. Top assignees: The UAB Research Foundation (The University of Alabama at Birmingham), Duke University, University of Pennsylvania. Active years: 1998-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George M Shaw. Retrieved from https://idiyas.com/inventor/george-m-shaw

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 20 (Patent Applications = 6)

% Patents Active = 65.0

CIPO Patents = 3 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 5.4

ph-index = 3

Forward Citations = 75(Granted Patents)

Location History:

Birmingham, AL (US) (1998 - 2021)
Wallingford, PA (US) (2016 - 2023)
Philadelphia, PA (US) (2018 - 2023)

Company Filing History:

9 out of 641

The UAB Research Foundation (The University of Alabama at Birmingham)

University of Pennsylvania

patents

4. 5 out of 3,699

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

5. 3 out of 3,806

Johns Hopkins University

patents

6. 3 out of 314

Triad National Security, LLC

patents

7. 3 out of 1,223

Vanderbilt University

Leland Stanford Junior University

patents

10. 2 out of 576

Los Alamos National Security, LLC

patents

11. 2 out of 1,217

The United States of America as Represented by the Department of Health

patents

12. 1 out of 250

The Administrators of the Tulane Educational Fund

patents

13. 1 out of 1,330

The University of North Carolina at Chapel Hill

patents

14. 1 out of 16,048

University of California

patents

15. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2025

Loading Chart...

Areas of Expertise:

Nucleoside-Modified mRNA

Lipid Nanoparticles

Hepatitis C Virus

Immunogens

Antibody Evolution

Protective Antibodies

HIV-1 Glycoproteins

Molecular Cloning

Viral Envelope Proteins

Nucleic Acids

Scaffolds

Genome Sequence

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12226471 - Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus (2025-02-18),

2. 11660332 - Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus (2023-05-30),

3. 11596679 - Hepatitis C virus gene sequences and methods of use therefor (2023-03-07),

4. 10946090 - Consensus/ancestral immunogens (2021-03-16),

5. 10849970 - Antibody evolution immunogens (2020-12-01),

6. 10561725 - Method of inducing the production of protective anti-HIV-1 antibodies (2020-02-18),

7. 10322141 - Compositions comprising CH848 envelopes and uses thereof (2019-06-18),

8. 10004800 - Antibody evolution immunogens (2018-06-26),

9. 9844589 - Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses (2017-12-19),

10. 9309574 - Molecular cloning of HIV-1 from immortalized cell lines (2016-04-12),

11. 8647818 - Molecular scaffolds for HIV-1 immunogens (2014-02-11),

12. 8637234 - Molecular scaffolds for HIV-1 epitopes (2014-01-28),

13. 8071107 - Nucleic acids encoding modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins (2011-12-06),

14. 7169396 - Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1 (2007-01-30),

15. 6897301 - Reference clones and sequences for non-subtype B isolates of human immunodeficiency virus type 1 (2005-05-24),

Title: **George M Shaw: A Pioneer in Hepatitis C Vaccine Development**

Introduction

George M Shaw is an innovative inventor based in Birmingham, Alabama, who has made significant contributions to medical research, particularly in the field of vaccines. With a total of 19 patents to his name, his work focuses on advancing our understanding and treatment of hepatitis C virus (HCV), a critical concern in global health.

Latest Patents

Shaw's latest patents reflect his commitment to finding effective solutions against HCV. His inventions include a "Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus," which pertains to compositions and methods aimed at inducing an adaptive immune response against HCV. This patent outlines compositions that may include a nucleoside-modified nucleic acid molecule encoding a HCV antigen along with an adjuvant, highlighting his innovative approach to vaccine development. Another prominent patent is focused on "Hepatitis C virus gene sequences and methods of use therefor," which also aims to induce a robust immune response against HCV through similar sophisticated compositions.

Career Highlights

Throughout his illustrious career, George M Shaw has worked at prestigious institutions such as Duke University and the University of Pennsylvania. These respected organizations have provided a platform for his research endeavors, aiding in the development of groundbreaking vaccines that contribute to infectious disease management.

Collaborations

Collaboration has been a key component of Shaw's success. He has worked alongside renowned scientists, including Beatrice H Hahn and Feng Gao, exchanging knowledge and expertise that enhances the quality and impact of their collective research efforts.

Conclusion

George M Shaw's contributions to the field of vaccine development are noteworthy and demonstrate his role as a leading inventor in the fight against hepatitis C. As he continues to innovate and collaborate, his work holds promise for improving health outcomes for individuals affected by this virus, solidifying his legacy in medical research.

Profile summary based on public USPTO records.